// App-Quantinova.ai

1473 : CXCL12 inhibition with NOX-A12 (olaptesed pegol) increases T-cell infiltration in tumor-stroma spheroids and synergizes with PD-1 immune checkpoint blockade

Researchers

Presenter

  • Dirk Zboralski

Principal Investigators

  • Lisa Bauer

  • Dirk Eulberg

  • Axel Vater

Medical Centers

  • NOXXON Pharma AG, Berlin, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

  • Stromal cell-derived factor 1

Drug/Treatment

  • NOX A12

  • NOX D19

  • Immunol

  • CXCL12

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved